Measuring Oral Vitamin B12 Bioavailability Using [13C]-cyanocobalamin in Humans. (29th May 2020)
- Record Type:
- Journal Article
- Title:
- Measuring Oral Vitamin B12 Bioavailability Using [13C]-cyanocobalamin in Humans. (29th May 2020)
- Main Title:
- Measuring Oral Vitamin B12 Bioavailability Using [13C]-cyanocobalamin in Humans
- Authors:
- Devi, Sarita
Pasanna, Roshni
Shamshuddin, Zeeshan
Bhat, Kishor
Sivadas, Ambily
Mandal, Amit
Kurpad, Anura - Abstract:
- Abstract: Objectives: To biosynthesize a stable-isotope labeled [ 13 C]-cyanocobalamin and to measure its bioavailability in humans. Methods: Salmonella enterica was precultured in Luria-Bertani medium and single-cell colonies were grown in No carbon E medium, supplemented with [ 13 C]-ethanolamine as a sole-carbon source along with other precursors (dicyanocobinamide and dimethylbenzimidazole) and incubated for 48 h at 30°C and centrifuged. The pellets were resuspended in methanol/sodium cyanide and incubated overnight and extracts were purified by HPLC. The peaks corresponding to standard cyanocobalamin were collected and characterized by MALDI-MS. After animal testing, healthy young subjects were orally administered with [ 13 C]-cyanocobalamin in a protocol that included hourly blood sampling for 12 h post-dose, and daily sampling for the next 5 days, to characterize its kinetics at a higher dose than the daily requirement (∼10x, n = 4, 2 males and females) and its appearance was modeled using a two-compartment model with early and late absorption phases. The same model was applied for lower dose at daily requirement (∼2.5 μg, n = 11 males), with sampling for 12 h post-dose. In addition, the effect of co-ingested food (n = 1, male) and the effect of parenteral replenishment of existing body vitamin B12 stores by intramuscular injection of 1 mg hydroxocobalamin, (n = 3, males) on bioavailability was also studied. The appearance of tracer in plasma was quantified byAbstract: Objectives: To biosynthesize a stable-isotope labeled [ 13 C]-cyanocobalamin and to measure its bioavailability in humans. Methods: Salmonella enterica was precultured in Luria-Bertani medium and single-cell colonies were grown in No carbon E medium, supplemented with [ 13 C]-ethanolamine as a sole-carbon source along with other precursors (dicyanocobinamide and dimethylbenzimidazole) and incubated for 48 h at 30°C and centrifuged. The pellets were resuspended in methanol/sodium cyanide and incubated overnight and extracts were purified by HPLC. The peaks corresponding to standard cyanocobalamin were collected and characterized by MALDI-MS. After animal testing, healthy young subjects were orally administered with [ 13 C]-cyanocobalamin in a protocol that included hourly blood sampling for 12 h post-dose, and daily sampling for the next 5 days, to characterize its kinetics at a higher dose than the daily requirement (∼10x, n = 4, 2 males and females) and its appearance was modeled using a two-compartment model with early and late absorption phases. The same model was applied for lower dose at daily requirement (∼2.5 μg, n = 11 males), with sampling for 12 h post-dose. In addition, the effect of co-ingested food (n = 1, male) and the effect of parenteral replenishment of existing body vitamin B12 stores by intramuscular injection of 1 mg hydroxocobalamin, (n = 3, males) on bioavailability was also studied. The appearance of tracer in plasma was quantified by Q-Exactive-Orbitrap-MS. Results: Biosynthesized [ 13 C]-cyanocobalamin was labeled with up to 7– 13 [C] atoms and at a daily requirement dose (∼2.5 μg), its mean bioavailability was 50.4 ± 8.2%, but this was also dependent on the existing body store of vitamin B12 . Two-weeks after replenishing the body stores, bioavailability increased by 1.5-fold (from 45.6 ± 0.02% to 67.8 ± 0.06%). At a higher dose (∼20 μg), its bioavailability was 6.0 ± 1.2% but the absolute amount absorbed was similar to that with the low dose. Conclusions: A novel stable isotope-based vitamin B12 bioavailability assessment is described at low and high doses. This has implications toward rationalizing dosages used in clinical supplementation and public health fortification programs. Funding Sources: Department of Biotechnology, India (to SD and AVK) and by the Wellcome Trust/DBT India Alliance Margdarshi Fellowshi p [No. IA/M/14/1/501, 681] awarded to AVK. … (more)
- Is Part Of:
- Current developments in nutrition. Volume 4(2020)Supplement 2
- Journal:
- Current developments in nutrition
- Issue:
- Volume 4(2020)Supplement 2
- Issue Display:
- Volume 4, Issue 2 (2020)
- Year:
- 2020
- Volume:
- 4
- Issue:
- 2
- Issue Sort Value:
- 2020-0004-0002-0000
- Page Start:
- 1794
- Page End:
- 1794
- Publication Date:
- 2020-05-29
- Subjects:
- Nutrition -- Periodicals
Nutritional Physiological Phenomena
Nutrition
Periodicals
Periodicals
Fulltext
Internet Resources
Periodicals
612.3 - Journal URLs:
- https://academic.oup.com/cdn ↗
https://www.sciencedirect.com/journal/current-developments-in-nutrition ↗
https://cdn.nutrition.org/ ↗
http://www.oxfordjournals.org/ ↗ - DOI:
- 10.1093/cdn/nzaa067_021 ↗
- Languages:
- English
- ISSNs:
- 2475-2991
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15319.xml